WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity
WuXi Biologics continues to deliver record results
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Novel Immune Check Point Bispecifics for $220 Million

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA
WuXi Biologics Wins SCRIP Award for “Best Company in an Emerging Market”

WuXi Biologics Selected as Forbes Asia’s  Best Under A Billion  2018
March 25-27, 2019
April 8-12, 2019